Can the SIARI score be used at initial admission to predict testes involvement in patients with fournier's gangrene; a single-centre, retrospective study.


Journal

BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571

Informations de publication

Date de publication:
14 Aug 2024
Historique:
received: 04 12 2023
accepted: 30 07 2024
medline: 14 8 2024
pubmed: 14 8 2024
entrez: 13 8 2024
Statut: epublish

Résumé

To predict testicular involvement in patients diagnosed with Fournier's gangrene (FG) using the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score and the site other than lower limb (SIARI) score. The medical records of 51 patients operated for FG in our clinic between December 2012 and April 2022 were evaluated retrospectively in this study. Patients' demographics, and laboratory test results were compared with the testisticular involvement status. Patients with testisticular involvement (n = 10) were compared with patients without testicular involvement (n = 41). The SIARI score at initial admission was analysed using logistic regression analyses for its performance in predicting testicular involvement with FG. Receiver operating characteristics (ROC) curves and the area under the receiver operating characteristic curve (AUROC) were used to evaluate its discriminating ability. The SIARI score had modest performance for diagnosing testicular involvement in FG patients, with ROC analysis showing an AUROC value of 0.83 (p < 0.001). With a SIARI cut-off score of ≥ 3, the sensitivity was 90% and the specificity was 68%. For a SIARI cut-off score of ≥ 5, the sensitivity was 40% and the specificity was 97%. The ability of the SIARI score to discriminate FG with testicular involvement is modest. The SIARI score should be employed cautiously as a routine diagnostic tool for the prediction of testicular involvement in FG at the initial admission. More research is needed to develop a better understanding of the relationship between the SIARI score and testicular involvement in FG.

Sections du résumé

BACKGROUND BACKGROUND
To predict testicular involvement in patients diagnosed with Fournier's gangrene (FG) using the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score and the site other than lower limb (SIARI) score.
METHODS METHODS
The medical records of 51 patients operated for FG in our clinic between December 2012 and April 2022 were evaluated retrospectively in this study. Patients' demographics, and laboratory test results were compared with the testisticular involvement status. Patients with testisticular involvement (n = 10) were compared with patients without testicular involvement (n = 41). The SIARI score at initial admission was analysed using logistic regression analyses for its performance in predicting testicular involvement with FG. Receiver operating characteristics (ROC) curves and the area under the receiver operating characteristic curve (AUROC) were used to evaluate its discriminating ability.
RESULTS RESULTS
The SIARI score had modest performance for diagnosing testicular involvement in FG patients, with ROC analysis showing an AUROC value of 0.83 (p < 0.001). With a SIARI cut-off score of ≥ 3, the sensitivity was 90% and the specificity was 68%. For a SIARI cut-off score of ≥ 5, the sensitivity was 40% and the specificity was 97%.
CONCLUSIONS CONCLUSIONS
The ability of the SIARI score to discriminate FG with testicular involvement is modest. The SIARI score should be employed cautiously as a routine diagnostic tool for the prediction of testicular involvement in FG at the initial admission. More research is needed to develop a better understanding of the relationship between the SIARI score and testicular involvement in FG.

Identifiants

pubmed: 39138463
doi: 10.1186/s12894-024-01557-x
pii: 10.1186/s12894-024-01557-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173

Informations de copyright

© 2024. The Author(s).

Références

Selvi I, Aykac A, Baran O, Burlukkara S, Ozok U, Sunay MM. A different perspective for morbidity related to Fournier’s gangrene: which scoring system is more reliable to predict requirement of skin graft and flaps in survivors of Fournier’s gangrene? Int Urol Nephrol. 2019;51(8):1303–11. https://doi.org/10.1007/s11255-019-02188-0 .
doi: 10.1007/s11255-019-02188-0 pubmed: 31177367
Ozkan OF, et al. Fournier’s gangrene current approaches. Int Wound J. Oct. 2016;13(5):713–6. https://doi.org/10.1111/iwj.12357 .
Yücel M, Özpek A, Baþak F, Kýlýç A, Ünal E, Yüksekdað S, Acar A, Baþ G. Fournier’s gangrene: A retrospective analysis of 25 patients. Turkish Journal of Trauma and Emergency Surgery. 2017 Sep 1;23(5):400–4. https://doi.org/10.5505/tjtes.2017.01678 .
Boughanmi F, Ennaceur F, Korbi I, Chaka A, Noomen F, Zouari K. Fournier’s gangrene: its management remains a challenge. Pan Afr Med J. 2021;38:23. https://doi.org/10.11604/pamj.2021.38.23.25863 .
doi: 10.11604/pamj.2021.38.23.25863 pubmed: 33777291 pmcid: 7955597
Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Critical care medicine. 2004 Jul 1;32(7):1535–41. https://doi.org/10.1097/01.ccm.0000129486.35458.7d .
Cribb BI, Wang MTM, Kulasegaran S, Gamble GD, MacCormick AD. The SIARI Score: A Novel Decision Support Tool Outperforms LRINEC Score in Necrotizing Fasciitis. World J. Surg. Oct. 2019;43(10):2393–400. https://doi.org/10.1007/s00268-019-05061-4 .
Sarkis P, Farran F, Khoury R, Kamel G, Nemr E, Biajini J, Merheje S. [Fournier’s gangrene: a review of the recent literature]. Prog. en Urol. J. l’Association Fr. d’urologie la Soc. Fr. d’urologie, Feb. 2009;19(2):75–84. https://doi.org/10.1016/j.purol.2008.09.050 .
Sorensen MD, et al. Fournier’s Gangrene: population based epidemiology and outcomes. J Urol. May 2009;181(5):2120–6. https://doi.org/10.1016/j.juro.2009.01.034 .
Medina Polo J, Tejido Sánchez A, de la Rosa F, Kehrmann N, Felip Santamaría MB, Alvarez, Galvis OL. [Fournier gangrene: evaluation of prognostic factors in 90 patients]. Actas Urol Esp. 2008;32(10):1024–30. https://doi.org/10.1016/s0210-4806(08)73982-2 .
doi: 10.1016/s0210-4806(08)73982-2 pubmed: 19143295
Vyas HG, Kumar A, Bhandari V, Kumar N, Jain A, Kumar R. Prospective evaluation of risk factors for mortality in patients of Fournier’s gangrene: A single center experience. Indian J. Urol. Jul. 2013:29(3):161–65. https://doi.org/10.4103/0970-1591.117255 .
Mallikarjuna MN, Vijayakumar A, Patil VS, Shivswamy BS. Fournier’s Gangrene: current practices. ISRN Surg. 2012;2012:942437. https://doi.org/10.5402/2012/942437 .
doi: 10.5402/2012/942437 pubmed: 23251819 pmcid: 3518952
Benjelloun EB, et al. Fournier’s gangrene: our experience with 50 patients and analysis of factors affecting mortality. World J Emerg Surg. Apr. 2013;8(1):13. https://doi.org/10.1186/1749-7922-8-13 .
Czymek R, Schmidt A, Eckmann C, Bouchard R, Wulff B, Laubert T, Limmer S, Bruch H-P, Kujath P. Fournier’s gangrene: vacuum-assisted closure versus conventional dressings. Am. J. Surg. Feb. 2009;197(2):168–76. https://doi.org/10.1016/j.amjsurg.2008.07.053 .
Shyam DC, Rapsang AG. Fournier’s gangrene. Surgeon. Aug. 2013;11(4):222–32. https://doi.org/10.1016/j.surge.2013.02.001 .
Ullah S, Khan M, Jan MAU. Fournier’s gangrene: a dreadful disease. Surgeon. Jun. 2009;7(3):138–42. https://doi.org/10.1016/s1479-666x(09)80036-x .
Rajbhandari SM, Wilson RM. Unusual infections in diabetes. Diabetes Res Clin Pract. Feb. 1998;39(2):123–8. https://doi.org/10.1016/s0168-8227(97)00125-3 .
Nisbet AA, Thompson IM. Impact of diabetes mellitus on the presentation and outcomes of Fournier’s gangrene. Urology. Nov. 2002;60(5):775–79. https://doi.org/10.1016/s0090-4295(02)01951-9 .
Sockkalingam VS, Subburayan E, Velu E, Rajashekar ST, Swamy AM. Fournier’s gangrene: prospective study of 34 patients in South Indian population and treatment strategies. Pan Afr Med J. 2018;31. https://doi.org/10.11604/pamj.2018.31.110.15495 .
Hubert J, Fournier G, Mangin P, Punga-Maole M. [Gangrene of the external genitalia]. Prog. en Urol. J. l’Association Fr. d’urologie la Soc. Fr. d’urologie. Dec. 1995;5(6):911–24.
Smith GL, Bunker CB, Dinneen MD. Fournier’s gangrene. Br. J. Urol. Mar. 1998;81(3):347–55. https://doi.org/10.1046/j.1464-410x.1998.00532.x .
Taviloglu K Cabioglu N, Cagatay A, Yanar H, Ertekin C, Baspinar I, Ozsut H, Guloglu R. Idiopathic necrotizing fasciitis: risk factors and strategies for management. Am. Surg. Apr. 2005;71(4):315–20.
Ozkan OF, Altýnlý E, Koksal N, Senger S, Celik A. Combining Flexi-Seal and negative pressure wound therapy for wound management in Fournier’s gangrene. International wound journal. Jun. 2015;12(3):364–65. https://doi.org/10.1111/iwj.12103 .
Canbaz H, et al. [Fournier’s gangrene: analysis of risk factors affecting the prognosis and cost of therapy in 18 cases]. Ulus travma ve acil Cerrahi Derg = Turkish J Trauma Emerg Surg TJTES. Jan. 2010;16(1):71–6.
Aliyu S, G Ibrahim A, Ali N, M Waziri A. Fournier’s gangrene as seen in University of Maiduguri Teaching Hospital. ISRN Urol. 2013;2013:673121. https://doi.org/10.1155/2013/673121 .
doi: 10.1155/2013/673121 pubmed: 23997966 pmcid: 3753747
Hsiao C-T, Chang C-P, Huang T-Y, Chen Y-C, Fann W-C. Prospective validation of the Laboratory Risk Indicator for necrotizing Fasciitis (LRINEC) score for necrotizing Fasciitis of the extremities. PLoS ONE. 2020;15(1):e0227748. https://doi.org/10.1371/journal.pone.0227748 .
doi: 10.1371/journal.pone.0227748 pubmed: 31978094 pmcid: 6980593
Liao C-I, Lee Y-K, Su Y-C, Chuang C-H, Wong C-H. Validation of the laboratory risk indicator for necrotizing fasciitis (LRINEC) score for early diagnosis of necrotizing fasciitis. Tzu Chi Med. J. Jun. 2012;24(2):73–6. https://doi.org/10.1016/j.tcmj.2012.02.009 .
Wu H, Liu S, Li C, Song Z. Modified Laboratory Risk Indicator for necrotizing Fasciitis (m-LRINEC) score system in diagnosing necrotizing fasciitis: a nested case-control study. Infect Drug Resist. 2021;14:2105–12. https://doi.org/10.2147/IDR.S313321 .
doi: 10.2147/IDR.S313321 pubmed: 34113137 pmcid: 8187035
Kishino T et al. Jun., Usefulness of serum procalcitonin for necrotizing fasciitis as an early diagnostic tool., J. Infect. Chemother. Off. J. Japan Soc. Chemother. 2021;27(6):787–93. https://doi.org/10.1016/j.jiac.2021.01.002
Wetterauer C, et al. A contemporary case series of Fournier’s gangrene at a Swiss tertiary care center-can scoring systems accurately predict mortality and morbidity? World J Emerg Surg. 2018;13:25. https://doi.org/10.1186/s13017-018-0187-0 .
doi: 10.1186/s13017-018-0187-0 pubmed: 29977327 pmcid: 6014016
Narasimhan V, Ooi G, Weidlich S, Carson P. Laboratory Risk Indicator for necrotizing Fasciitis score for early diagnosis of necrotizing fasciitis in Darwin. ANZ J Surg. Jan. 2018;88:1–2. https://doi.org/10.1111/ans.13895 .
Bechar J, Sepehripour S, Hardwicke J, Filobbos G. Laboratory risk indicator for necrotising fasciitis (LRINEC) score for the assessment of early necrotising fasciitis: a systematic review of the literature. Ann R Coll Surg Engl. May 2017;99(5):341–6. https://doi.org/10.1308/rcsann.2017.0053 .
R K, Tandup C, Reddy D, Jayant D, Naik K, Sahu S, Thakur V, Khare S, Sakaray Y, Irrinki S, Kaman L. Prospective Validation and Comparison of Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) and Site Other Than Lower Limb, Immunosuppression, Age, Renal Impairment, and Inflammatory Markers (SIARI) Scoring Systems for Necrotizing Fasciitis. J. Surg. Res. Mar. 2023;283:719–25. https://doi.org/10.1016/j.jss.2022.11.001 .
Tarricone A, et al. A systematic review and Meta-analysis of the effectiveness of LRINEC score for Predicting Upper and Lower Extremity necrotizing Fasciitis. J foot Ankle Surg off Publ Am Coll Foot Ankle Surg. 2022;61(2):384–9. https://doi.org/10.1053/j.jfas.2021.09.015 .
doi: 10.1053/j.jfas.2021.09.015

Auteurs

Anil Erdik (A)

Department of Urology, Sakarya Sadıka Sabancı Hospital, Sakarya, 54580, Turkey. anilerdik@gmail.com.

Kemal Demirhan (K)

Department of Urology, School of Medicine, Sakarya University, Sakarya, 54100, Turkey.

Haci Ibrahim Cimen (HI)

Department of Urology, School of Medicine, Sakarya University, Sakarya, 54100, Turkey.

Yavuz Tarik Atik (YT)

Department of Urology, School of Medicine, Sakarya University, Sakarya, 54100, Turkey.

Deniz Gul (D)

Department of Urology, School of Medicine, Sakarya University, Sakarya, 54100, Turkey.

Osman Kose (O)

Department of Urology, School of Medicine, Sakarya University, Sakarya, 54100, Turkey.

Hasan Salih Saglam (HS)

Department of Urology, School of Medicine, Sakarya University, Sakarya, 54100, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH